Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer

ImmunityBio (NASDAQ:IBRX), which develops immunotherapies and vaccines for cancers and infectious diseases, closed Wednesday at $8.54, up 41.86%. The stock jumped after the European Commission granted conditional marketing authorization for Anktiva to treat bladder cancer. Trading volume reached 78.5 million shares, about 178% above its three-month average of 28.2 million shares. ImmunityBio IPO'd in 2015 and has fallen 75% since going public. How the markets moved today The S&P 500 rose 0.53% to finish ...